Current stock page

Stock Analysis

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis

Dianthus Therapeutics, Inc. (DNTH) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

DNTH Stock Analysis Summary

Dianthus Therapeutics, Inc. (DNTH) currently has an AIQ Score of 56/100, indicating a neutral setup. Risk is the strongest factor at 58/100. Quality is the weakest current factor at 52/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

DNTH at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$91.81
AIQ Score56/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$5.26B
P/E Ratio (TTM)3,060.33
Forward P/E—
EPS (Q3 FY2026)-$0.81
Revenue (Q3 FY2026)$1.21M
Dividend Yield (TTM)0.00%
Beta0.97
Volume681.52K
52-week range$34.29-$117.88
RSI 1462.93
50-Day SMA$88.45
200-Day SMA$86.93
Analyst Price Target$134.00
Next EarningsMar 8, 2027
As of Nov 13, 2026 · Market close

DNTHDianthus Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$91.81−$0.67 (−0.72%)

Latest quote

  • Momentum
    58
  • Value
    —
  • Quality
    52
  • Risk resilience
    58
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

DNTH Stock Analysis Summary

Dianthus Therapeutics, Inc. (DNTH) currently has an AIQ Score of 56/100, indicating a neutral setup. Risk resilience is the strongest factor at 58/100. Quality is the weakest current factor at 52/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, DNTH has AIQ Score of 56/100 with Risk resilience base of 58/100 and fading Quality at 52/100. Wait for component alignment before adding exposure.

Healthcare · -0.72% stock move · DNTH classified in Biotechnology.

Current Evidence

NeutralDNTH is in a neutral AIQ regime; Risk resilience is the strongest visible factor at 58/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is DNTH Bullish or Bearish Right Now?

DNTH currently has a neutral overall setup. Momentum is the strongest factor at 58/100, while Quality is weakest at 52/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Price is +3.80% above its 50-day SMA.
  • - Analyst target implies +45.95% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (34 vs 10).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

DNTH's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 2 neutral, and 10 sell votes. DNTH's 14-day RSI is 62.93, which places the stock in a constructive momentum range. DNTH's beta is 0.97, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in DNTH?

The largest recent change in DNTH is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+5.0
Quality
+1.0
Risk
+0.0

What Would Change the DNTH Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

DNTH Decision Framework

Public evidence layers, setup checks, and risk context for Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis

Dianthus Therapeutics, Inc. has an AIQ Score of 56/100 in a Neutral regime. Momentum is strongest at 58/100. Beta is 0.97, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextDNTH is in a Neutral AIQ regime with score 56/100.
Signal ConflictThe primary conflict is that momentum leads at 58/100 while quality lags at 52/100.
Factor EvidenceMomentum 58/100 · Quality 52/100 · Risk 58/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 58/100.

TimingWait

Momentum is 58/100 and RSI (14) is 62.9.

Regime fitWait

DNTH is in a Neutral regime at 56/100.

Risk controlWait

Risk factor is 58/100 with beta 0.97 and annual volatility 59.79%.

ConflictPass

Current conflict: momentum leads at 58/100 while quality lags at 52/100.

AIQ Score
56/100
Price
$91.81
Beta
0.97
RSI (14)
62.9

DNTH Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

DNTH Fundamentals

DNTH valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$1.21M
Net income
-$46.64M
Free cash flow
-$50.7M
View full DNTH fundamental analysis

DNTH Technical Analysis

DNTH technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
62.93
Price vs SMA-50
+3.80%
View full DNTH technical analysis

DNTH Stock Catalysts

Track DNTH earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 8, 2027
Analyst target
$134.00
News items
0
View DNTH earnings and stock catalysts

DNTH Dividend Analysis

DNTH dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View DNTH dividend history and analysis

DNTH Financial Data

DNTH revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$1.21M
EPS
-$0.81
Periods
8
View DNTH financials

DNTH Risk Analysis

DNTH volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.97
Risk score
58/100
1Y volatility
59.79%
View DNTH risk analysis

DNTH Stock News

DNTH stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read DNTH stock news

DNTH vs Biotechnology Peers

Current peer cohort: DNTH · DYN · ELVN · ERAS · EWTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
DNTH
Current stock
56/100—58/10058/1001.8259.79%Current
DYN
Dyne Therapeutics, Inc.
48/100—52/10042/1000.1163.89%DNTH vs DYN
ELVN
Enliven Therapeutics, Inc.
71/100—66/10056/1001.4378.19%DNTH vs ELVN
ERAS
Erasca, Inc.
61/100—67/10039/1002.29102.70%DNTH vs ERAS
EWTX
Edgewise Therapeutics, Inc.
72/100—82/10057/1001.4173.21%DNTH vs EWTX
Pairwise Compare links: DYN · ELVN · ERAS · EWTXDNTH vs DYNDNTH vs ELVNDNTH vs ERASDNTH vs EWTXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a DNTH stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for DNTH: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
3,060.33
As of Nov 13, 2026
Revenue growth
205.56%
Gross margin
97.20%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$1.21M
Quarter net income
-$46.64M
Quarter free cash flow
-$50.7M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
62.93
MACD
1.33

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
58/100
Beta
0.97
Annual volatility
59.79%
Max drawdown
-37.83%

DNTH Stock FAQ

What is DNTH stock price today?

Dianthus Therapeutics, Inc.'s current stock price is $91.81. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is DNTH bullish or bearish right now?

DNTH's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is DNTH's market cap?

DNTH's market cap is $5.26B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is DNTH's current P/E ratio?

DNTH's current P/E ratio is 3,060.33 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is DNTH's RSI?

DNTH's 14-day RSI is 62.93 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is DNTH above its 50-day and 200-day moving averages?

DNTH is 3.80% from its 50-day SMA and 5.62% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is DNTH's next earnings date?

DNTH's next earnings date is currently listed as Mar 8, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does DNTH pay a dividend?

DNTH's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.